[Tolerance of a new oral long-acting theophylline in patients with obstructive airway diseases].
In an open study with 306 hospitalized patients with obstructive airway diseases (149 males aged 57.2 +/- 13.0 years, 157 females aged 52.2 +/- 13.9 years), the tolerance of the new sustained-release theophylline preparation Uniphyllin was investigated. The duration of treatment was 3.1 +/- 1.3 weeks (males) or 2.9 +/- 1.2 weeks (females), respectively. For 75% of the male and 85% of the female patients a single evening dosage was sufficient. The number of side effects necessitating discontinuance of the theophylline therapy in females was three times that observed in males. Altogether, the 7.8% drop-out rate was very low, considering the seriously ill patients participating in the study. Accordingly, the new sustained-release theophylline preparation has been tolerated particularly well.